Navigating the pandemic operating room: How COVID-19 infection timing affects complications in orthopedic oncologic surgery
Article History
-
Received: ,
Accepted: ,
Abstract
Abstract
To elucidate the effects of COVID-19 positivity within 12 weeks preceding metastasis-related surgical procedures on postoperative complications.
We retrospectively analyzed 20,104,963 patients, of which 109,127 underwent surgery for metastatic processes. Patients were categorized based on COVID-19 status within 12 weeks of surgery: positive (1.49 %) and negative (98.51 %). Variables assessed included demographic data, body mass index (BMI), Charlson Comorbidity Index (CCI) scores, and various postoperative complications, such as venous thromboembolism (VTE), 30-day and 365-day all-cause mortality.
The COVID-19 positive cohort exhibited a significantly higher BMI (32.41 ± 8.14 vs. 33.43 ± 7.56, p < 0.001) and CCI score (2.94 ± 3.06 vs. 2.67 ± 2.89, p < 0.001). Additionally, they demonstrated elevated rates of VTE (2.64 % vs. 1.36 %), 30-day mortality (1.65 % vs. 0.39 %), and 365-day mortality (5.71 % vs. 2.02 %). Adjusted multivariate logistic regression highlighted COVID-19 positivity within 0–2 weeks of surgery and CCI >3 as significant predictors of VTE, 30-day, and 365-day mortality. Adjusted odds ratios associated with recent COVID-19 positivity for VTE, sepsis, surgical site infection, 30-day mortality, and 365-day mortality were 2.69, 1.74, 0.98, 5.49, and 4.27, respectively. For CCI>3, the respective odds ratios were 2.10, 5.03, 1.89, 6.33, and 9.04. Owing to limited events, odds ratios for bleeding and AKI were not established.
Patients positive for COVID-19 within 12 weeks of metastasis-related surgery face heightened postoperative complications, particularly when positivity is within 0–2 weeks of surgery. Additionally, a CCI score >3 further augments this risk, emphasizing the need for meticulous perioperative management and strategic patient selection in the era of COVID-19.
Keywords
This article was originally published by Reed Elsevier India Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
1 Background
Bone is one of the primary sites for cancer metastasis, often developing from prevalent malignancies such as breast, lung, prostate, or kidney cancer.1 These metastatic tumors possess the capacity to compromise bone structural integrity, leading to fractures, instability, and severe pain. Involvement of spinal vertebrae can trigger extensive nerve pain and severe complications, including spinal cord compression.2–4 Given the recent strides in targeted oncologic therapies, individuals with cancer are experiencing prolonged survival. As a result, orthopedic surgeons are tasked with the responsibility of maintaining patients’ quality of life by adeptly managing symptoms related to bone metastases.5
Orthopedic oncologic procedures for metastatic bone disease aim to excise tumors, stabilize affected bones and manage debilitating symptoms such as pain and functional impairment. These surgeries often involve the resection of metastatic lesions to address structural instability caused by pathological fractures or impending fractures.6 In cases where bone metastases lead to significant mechanical instability, tumor resection is generally preferred, particularly for weight-bearing bones.7,8 Beyond excising tumors, these interventions preserve healthy tissue, alleviate pain, and optimize functionality for patients with metastatic malignancies [3.5].
Surgical approaches – open versus minimally invasive-are determined by factors such as tumor location, size, and the extent of bone or soft tissue involvement, as assessed through pre-operative imaging and tissue biopsies.9 Bone reconstruction techniques, including the use of bone grafts, prosthetic implants and endoprostheses, are employed to restore skeletal integrity after tumor resection.10 Internal fixation devices, such as screws, plates, and intramedullary nails, may also be utilized to provide additional stability support.11 These measures collectively work to optimize functionality while reducing complications in patients with metastatic bone disease.
Given the complexity of these procedures and their inherent risks, understanding the impact of COVID-19 infection on patient outcomes is critical. COVID-19 pandemic has curtailed oncologic surgical case volume, with procedures declining by 12–50 % compared to pre-pandemic years.12 Orthopedic metastatic procedures inherently carry risks associated with infections, implants, bone healing, and functional limitations. When combined with a COVID-19 infection, these risks are heightened.13 COVID-19 compromises the immune system, increasing patients' susceptibility to infections and slowing wound healing.14 Respiratory issues elevate the risk for post-operative complications such as pneumonia or acute respiratory distress syndrome.14 Prolonged recovery in COVID-19 patients impedes rehabilitation and functional outcomes.13 Moreover, hospitals further expose patients to secondary infections, complicating the post-operative stay.15 Consequently, healthcare providers must carefully evaluate the risks, employ pre-operative COVID-19 testing, implement robust infection control measures, and closely monitor patients post-operatively to mitigate COVID-19's negative effects on orthopedic oncologic surgical outcomes.
Both cancer and COVID-19 can induce hypercoagulability.16–18 Cancer disrupts the delicate balance of the coagulation system, increasing clot risk through procoagulant (thrombin) release, endothelial damage, and generation of acute phase reactants.19 Anticancer interventions, such as surgery or chemotherapy, further heighten thrombotic risk.19 COVID-19 infection is also linked to a hypercoagulable state, increasing risk of thrombosis, deep vein thrombosis (DVT), and pulmonary embolism (PE).16 Combining cancer and COVID-19's hypercoagulable states may exacerbate the risk for thrombotic complications. Therefore, thrombosis, DVT, and PE pose significant risks to patients undergoing metastatic resection surgeries, especially for those who are at risk of COVID-19 infection.17 The aim of this study is to investigate if COVID-19 infection increases complication risk in metastatic orthopedic surgery. We hypothesize that patients with a COVID-19 diagnosis closest to their surgery date would exhibit the highest complication rates.
2 Methods, study design, and populations
The National COVID-19 Cohort Collaborative (N3C) is a research initiative that was established by the NIH to address critical research questions related to the COVID-19 pandemic. It brought together stakeholders to create a centralized data platform that integrated electronic health records from multiple institutions, providing access to extensive clinical and research data on COVID-19 patients.
We conducted a retrospective cohort study using data from the National COVID-19 Cohort Collaborative, which comprises data collected from March 15, 2020 to April 2023 from 80 major academic and community institutions. ICD-10 code U07.1 was used to identify COVID-19 positivity. This study included participants of all ages, and the COVID-19 positive cohort was compared with COVID-19 negative controls based on age, sex, race, diabetes, and hypertension. Comorbidity data was collected using ICD10 and ICD9 codes mapped to SNOMED CT codes. Rows with missing demographic data or outcome data were excluded.
3 Querying process
Patients who underwent metastatic orthopedic procedures were identified by utilizing specific Current Procedural Terminology (CPT) codes, including 23491, 23616, 24498, 27187, 27125, 27130, 27244, 27245, 27447, 27495, 27511, 27513, 27745. These procedures included complex spine and/or sacral/pelvic surgical procedures, soft tissue resections with appropriate reconstructive surgery, limb salvage procedures, surgical management of the complications of limb salvage surgery, management of distant metastatic disease, and pediatric oncologic cases. Patients in the COVID-19 positive group were included if they had a positive COVID-19 diagnosis within 90 days before their orthopedic oncologic surgery. This cohort was further stratified based on the timing of their COVID-19 diagnosis: 0–2 weeks before orthopedic oncologic surgery, 2–6 weeks before surgery, and 6–12 weeks before surgery. After identifying the COVID-19-positive and COVID-19-negative cohorts who underwent orthopedic oncologic surgery, we used ICD-10 codes to query for conditions such as pulmonary thrombosis, sepsis, acute kidney injury, surgical site infection, and death within 30 days of surgery. We selected patients who developed these respective complications within 0–84 days after their surgery.
4 Analysis variables
The primary independent variable in our study was COVID-19 positivity, which we defined as having a positive COVID-19 diagnosis 0–90 days before orthopedic oncologic surgery. Additional patient characteristics of interest included age, race, gender, body mass index, smoking status, diabetes, and hypertension. Our primary outcome was 30-day mortality, 365-day mortality, venous thromboembolic events, sepsis, acute kidney injury, and surgical site infection.
5 Statistical analysis
We used descriptive statistics to evaluate baseline patient characteristics. Continuous variables were expressed as Mean ± SD. Categorical variables were compared between groups using odds ratios. We considered p-values less than 0.05 to be statistically significant. We created two multivariate regression models. The first regression model was used to determine which predictor variables were significantly associated with our primary outcome. The second regression model was completed with only significant predictor models included to generate adjusted odds ratios.
6 Results
Out of 20,104,963 patients queried, 109,127 individuals underwent surgery related to metastatic processes. The study groups were comprised of patients who were positive for COVID-19 within 12 weeks of their surgery (1.49 %) and patients who were not COVID-10 positive within 12 weeks of their surgery (98.51 %) (Fig. 1). Age (67.8 ± 12.6 versus 68.2 ± 11.53.5, P = 0.121) and sex (F 57.4 % versus F 59.2 %, P = 0.154) were comparable between the two groups. BMI (32.41 ± 8.14 versus 33.43 ± 7.56, <0.001) and Charlson Comorbidity Index (CCI) Scores (2.94 ± 3.06 versus 2.67 ± 2.89, <0.001) differed between the two groups as the COVID-19 positive within 12 weeks of surgery group had higher BMIs and CCI scores (Table 1). Queried postoperative complications included DVT, sepsis, surgical site infection, bleeding, acute kidney injury (AKI), 30-day all-cause mortality, and 90-day all-cause mortality. The rates of VTE (2.64 % versus 1.36 %, p < 0.001), 30-day all-cause mortality (1.65 % versus 0.39 %, p < 0.001), and 365-day all-cause mortality (5.71 % versus 2.02 %, p < 0.001) were higher in the COVID-19 positive group compared to the COVID-19 negative group (Table 2) (see Fig. 2).


| Characteristic | Covid Diagnosis within 12 weeks of Surgery (n = 1627) | No Covid Diagnosis within 12 weeks of Surgery (n = 107,500) | P |
| Age,(y), (mean ± SD) | 67.77 (12.63) | 68.22 (11.53) | 0.121 |
| Sex, n (%) | 0.154 | ||
| Male | 42.59 % | 40.84 % | |
| Female | 57.41 % | 59.16 % | |
| Race, n (%) | 0.010 | ||
| White | 1345 (82.66 %) | 90,428 (84.11 %) | |
| Black or African American | 234 (14.38 %) | 14598 (13.58) | |
| Asian | 24 (1.47 %) | 1718 (1.59 %) | |
| BMI, (mean ± SD) | 32.41 (8.14) | 33.43 (7.56) | <0.001 |
| Charlson Comorbidity Index, (mean ± SD) | 2.94 (3.06) | 2.67 (2.89) | <0.001 |
| Clinical Outcome | Covid Diagnosis within 12 weeks of Surgery (n = 1627) | No Covid Diagnosis within 12 weeks of Surgery (n = 107,500) | P |
| VTE | 43 (2.64 %) | 1463 (1.36 %) | <0.001 |
| Sepsis | <20 | 1061 (0.98 %) | 0.311 |
| Surgical Site Infection | <20 | 1152 (1.07 %) | 0.331 |
| Bleeding | <20 | 25 (0.02 %) | 0.323 |
| AKI | <20 | 172 (0.16 % | 0.191 |
| 30DayMortality | 27 (1.65 %) | 423 (0.39 %) | <0.001 |
| 365DayMortality | 93 (5.71 %) | 2179 (2.02 %) | <0.001 |
On multivariate logistic regression, COVID 19 positivity within 0–2 weeks of surgery, and CCI score >3 were found to be significant predictors of VTE, 30-day all-cause mortality, and 365 day all-cause mortality. After adjusting for COVID positivity within 0–2 weeks of surgery, and CCI >3 score, COVID positivity within 0–2 weeks before surgery had the following adjusted odds ratios for DVT, sepsis, surgical site infection, 30-day all-cause mortality, and 365-day all-cause mortality: 2.69 (95 % CI [1.73,3.97]), 1.74 (95 % CI [0.92, 2.95]), 0.98 (95 % CI [0.42, 1.90]), 5.49 (95 % CI [3.11, 8.96]), and 4.27 (95 % CI [3.16, 5.66). CCI>3 had the following adjusted odds ratios for VTE, sepsis, surgical site infection, 30-day all-cause mortality, and 90-day all-cause mortality: 2.10 (95 % CI [1.90, 2.33]), 5.03 (95 % CI [4.43, 5.72]), 1.89 (95 % CI [1.69, 2.13]), 6.33 (95 % CI [5.16, 7.81]), 9.04 (95 % CI [8.18, 10.00]) (Table 3). No odds ratios were reported for bleeding and acute kidney injury because not enough cases occurred for model fit.
| VTE | |||
| Characteristic | Odds Ratio | Adjusted Odds Ratio | P |
| CCI > 3 | 2.00 [1.80, 2.23] | 2.10 [1.90, 2.33] | <0.001 |
| Covid Period 0–2 Weeks Before Surgery | 2.72 [1.74, 4.05] | 2.69 [1.73, 3.97] | <0.001 |
| Covid Period 2–6 Weeks Before Surgery | 1.83 [0.91, 3.24] | 1.81 [0.90, 3.21] | 0.066 |
| Covid Period 6–12Weeks Before Surgery | 1.18 [0.56, 2.15] | 1.16 [0.55, 2.11] | 0.665 |
| Sepsis | |||
| Characteristic | Odds Ratio | Adjusted Odds Ratio | P |
| CCI > 3 | 5.11 [4.48, 5.83] | 5.03 [4.43, 5.72] | <0.001 |
| Covid Period 0–2 Weeks Before Surgery | 1.67 [0.88, 2.84] | 1.74 [0.92, 2.95] | 0.061 |
| Covid Period 2–6 Weeks Before Surgery | 0.52 [0.09, 1.61] | 0.51 [0.08, 1.60] | 0.345 |
| Covid Period 6–12Weeks Before Surgery | 1.01 [0.40, 2.08] | 1.02 [0.40, 2.10] | 0.957 |
| Surgical Site Infection | |||
| Characteristic | Odds Ratio | Adjusted Odds Ratio | P |
| CCI > 3 | 2.06 [1.83, 2.33] | 1.89 [1.69, 2.13] | <0.001 |
| Covid Period 0–2 Weeks Before Surgery | 1.03 [0.44, 2.02] | 0.98 [0.42, 1.90] | 0.947 |
| Covid Period 2–6 Weeks Before Surgery | 0.68 [0.17, 1.78] | 0.67 [0.17, 1.76] | 0.496 |
| Covid Period 6–12Weeks Before Surgery | 0.48 [0.12, 1.26] | 0.49 [0.12, 1.27] | 0.216 |
| 30DayAllCauseMortality | |||
| Characteristic | Odds Ratio | Adjusted Odds Ratio | P |
| CCI > 3 | 6.06 [4.87, 7.58] | 6.33 [5.16, 7.81] | <0.001 |
| Covid Period 0–2 Weeks Before Surgery | 3.92 [2.11, 6.65] | 5.49 [3.11, 8.96] | 0.001 |
| Covid Period 2–6 Weeks Before Surgery | 4.40 [1.72, 9.18] | 4.01 [1.57, 8.29] | 0.023 |
| Covid Period 6–12Weeks Before Surgery | 2.19 [0.78, 4.82] | 2.57 [1.01, 5.30] | 0.001 |
| One YearAllCauseMortality | |||
| Characteristic | Odds Ratio | Adjusted Odds Ratio | P |
| CCI > 3 | 9.11 [8.21, 10.13] | 9.04 [8.18, 10.00] | <0.001 |
| Covid Period 0–2 Weeks Before Surgery | 3.59 [2.62, 4.81] | 4.27 [3.16, 5.66] | <0.001 |
| Covid Period 2–6 Weeks Before Surgery | 2.14 [1.20, 3.52] | 2.01 [1.14, 3.29] | 0.010 |
| Covid Period 6–12Weeks Before Surgery | 1.87 [1.17, 2.84] | 1.95 [1.24, 2.93] | 0.002 |
7 Discussion
While COVID-19 primarily affects respiratory function, thrombotic complications can develop in up to 13.4 % of infected individuals and in 79 % of patients admitted to the ICU.18,20,21 Postmortem investigations have revealed a substantial incidence of thrombosis, occurring in up to 81 % of COVID-19 patients.22 Previous research highlights elevated complication risk from recent COVID-19 infections in orthopedic surgeries like trauma,23 open reduction internal fixation (ORIF),24 and hip fracture repair.25 However, the interplay between recent COVID-19 infection and complex orthopedic oncologic procedures remains unexplored. Our study indicates COVID-19 diagnosis within 0-to-2 weeks of orthopedic oncologic surgery elevates risk for post-operative development of DVT, 30-day all-cause mortality, and 365-day all-cause mortality. This finding underscores the importance of carefully timing orthopedic tumor management surgery for recently infected COVID-19 patients to mitigate the risk of post-operative complications.26
Our research demonstrated that cancer patients who were infected with COVID-19 three or less weeks before metastatic orthopedic surgery experienced increased risk for VTE (AOR = 2.69, p < 0.001), 30-day mortality (AOR = 5.49, p < 0.001), and 365-day mortality (AOR = 4.27, p < 0.001) compared to those without recent infection. COVID-19 diagnoses 2–6 weeks and 6–12 weeks before orthopedic oncologic surgery also increased 30-day and 365-day mortality, with lower adjusted odd ratios than the 0–2-week COVID-19 positive cohort. Interestingly, COVID-19 diagnoses within 2–6 weeks and 6–12 weeks before metastatic oncologic surgery did not significantly increase rates of VTE. These results partially align with the retrospective cohort study conducted by Bryant et al. which found decreasing cardiovascular complications, like DVT and PE, with longer post-COVID surgery intervals.27 Evidence from a study by Deng et al. illustrated that elective surgery 0–4 weeks after mild to moderate COVID-19 infection is associated with an increased complication rate, yet procedures 4+ weeks after infection yielded lower complication risks.28 Considering this evidence, there likely exists a post-COVID state marked by inflammation and hypercoagulability. As with other viruses, the duration of the post-infection state is likely to vary between individuals, making it challenging to establish universal guidelines for surgical timing29,30 The current American Society of Anesthesiologists guidelines recommend delaying surgery for 4–12-weeks following a COVID-19 infection, depending on the severity of the infection and the patient's comorbidities.30 However, these guidelines are not surgery specific. Prospective studies are needed to underpin the exact mechanisms and timeline by which the interplay of COVID-19 and cancer can lead to increased rates of specific complications in orthopedic oncology surgery. Such findings would guide optimal timing for orthoaepdic oncologic surgery in recently infected COVID-19 patients.
Our study has important implications for developing orthopedic oncology surgical protocols following COVID-19 infection. Orthopedic surgeons must carefully assess timing for metastatic management in COVID-19 positive patients. Important factors to evaluate include disease severity, viral clearance, and overall patient health.31,32 In a recent systematic review, Khan et al. advocate for elective arthroplasty postponement surgery for 4–8 weeks in asymptomatic COVID-19 patients, 6–8 weeks in mild to moderate infections, and 12 weeks severe cases.33 A similar investigation focusing on orthopedic metastatic surgery could enhance surgical protocols and reduce post-operative complications for these patients. However, orthopedic tumor procedures may become urgent due to the advancing and debilitating nature of, and delaying surgery for too long could potentially worsen patient outcomes.34 Consequently, achieving a delicate equilibrium between the heightened risk of complications from a recent COVID-19 infection and the progression of cancer will require a collaborative approach involving surgeons, oncologists, and radiologists.
Further protocols should be formulated to enhance patient safety, minimize viral transmission, and ensure optimal timing of surgical interventions after COVID-19 infection.35,36 Developing a pre-operative scoring system to assess the risk of specific post-operative complications in patients undergoing metastatic oncologic surgery following a recent COVID-19 infection would be a prudent strategy. Such a tool could evaluate COVID-19 infection timing, metastatic tumor properties, and patient comorbidities. Ongoing research and collaboration between orthopedic surgeons and oncologists will facilitate the development of evidence-based guidelines, thereby guiding clinical decisions and improving the management of metastatic orthopedic surgeries in the context of COVID-19.
While our study provides insights into the association between the timing of pre-operative COVID-19 infection and complication risk in orthopedic oncologic surgery, it is important to recognize its inherent limitations. Our analysis is exclusively focused on patients undergoing metastatic management procedures, restricting our access to detailed orthopedic metrics, like metastatic lesion details, surgical extent, and pathological influences on outcomes. These procedures involve variable complexities due to diverse tissue manipulation, resection, and reconstruction techniques.37 Consequently, orthopedic metastatic management procedures can lead to complications such as nerve dysfunction, thrombotic events, or impaired healing38 Furthermore, metastatic lesions themselves compromise local blood supply, resulting in impaired healing, tissue necrosis, and increased infection susceptibility.39 Traits of metastatic lesions, such as size, location, and involvement of vital structures, amplify the surgical risks.40 Therefore, the observed association between COVID-19 infection timing and post-operative complications might be affected by each patient's distinct metastatic management procedure complexity and lesion severity. Due to the retrospective design of this study, it was impossible to control these differences.
Moreover, it is crucial to acknowledge the absence of an objective measure for the severity of COVID-19 infection may have influenced both the occurrence and severity of post-operative complications in our study. COVID-19 severity significantly impacts on the outcomes of metastatic oncologic surgery.40 Severe cases bring respiratory issues, heightened surgical infection susceptibility, thromboembolic events, organ dysfunction, and prolonged hospitalization, which hinder recovery.41 Thus, we must consider that we were not able to control for COVID-19 infection severity between the studied cohorts.
These limitations highlight the importance of further research and comprehensive data collection to gain a more thorough understanding of the intricate relationship between COVID-19 infection, timing of infection, and surgical outcomes in orthopedic oncology patients. It is necessary to consider not only the timing of COVID-19 diagnosis but also the severity of the infection when evaluating the potential risks and benefits of proceeding with metastatic orthopedic surgery.
8 Conclusion
In conclusion, our study underscores the importance of carefully considering the timing of COVID-19 diagnosis in relation to the scheduled date of orthopedic metastatic tumor surgery. Patients diagnosed with an active COVID-19 infection closer to the surgery, specifically within 3 weeks, face increased post-operative complication risks. For metastatic bone tumors, prudent practice may involve deferring surgery several weeks after the COVID-19 infection has resolved, thereby mitigating these risks. Our findings contribute to orthopedic protocols amidst the COVID-19 pandemic and highlight the need for a multidisciplinary approach to patient care in this complex clinical scenario. Subsequent research should elucidate the pathophysiology between COVID-19 infection and malignancy and provide post-infection timelines tailored to metastatic orthopedic surgery.
CRediT authorship contribution statement
Beshoy Gabriel: Writing – review & editing, Data analyzation. Henry Hoang: Writing – review & editing, Conceptualization. En Chang: Writing – review & editing. Justin P. Chan: Conceptualization, Formal analysis, Supervision.
Ethics in publishing statement
This research presents an accurate account of the work performed, all data presented are accurate and methodologies detailed enough to permit others to replicate the work.
This manuscript represents entirely original works and or if work and/or words of others have been used, that this has been appropriately cited or quoted and permission has been obtained where necessary.
This material has not been published in whole or in part elsewhere.
The manuscript is not currently being considered for publication in another journal.
That generative AI and AI-assisted technologies have not been utilized in the writing process or if used, disclosed in the manuscript the use of AI and AI-assisted technologies and a statement will appear in the published work.
That generative AI and AI-assisted technologies have not been used to create or alter images unless specifically used as part of the research design where such use must be described in a reproducible manner in the methods section.
All authors have been personally and actively involved in substantive work leading to the manuscript and will hold themselves jointly and individually responsible for its content.
This study utilized de-identified data from the National COVID Cohort Collaborative (N3C), supported by the National Center for Advancing Translational Sciences (NCATS). Data access was granted under the N3C Data Use Agreement, and all analyses were conducted in accordance with N3C and institutional guidelines. The dataset used was de-identified to protect patient confidentiality, and the study was exempt from human subjects review as determined by our Institutional Review Board. The authors declare no conflicts of interest. We thank the N3C team and NCATS for providing the dataset and supporting this research.
Informed consent statement
Not Applicable.
Funding
No funding for this project.
References
- How good are the outcomes of instrumented debulking operations for symptomatic spinal metastases and how long do they stand? A subgroup analysis in the global spine tumor study group database. Acta Neurochir (Wien). 2020;162(4):943-950.
- [Google Scholar]
- Minimally invasive interventional procedures for metastatic bone disease: a comprehensive review. Curr Oncol. 2022;29(6):4155-4177.
- [Google Scholar]
- Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discov Med. 2019;27(149):211-220.
- [Google Scholar]
- Management of skeletal metastases: an orthopaedic surgeon's guide. Indian J Orthop. 2015;49(1):83-100.
- [Google Scholar]
- Treatment of pathological fractures of the long bones. EFORT Open Reviews. 2016;1(5):136-145.
- [Google Scholar]
- Oncological and functional results after surgical treatment of bone metastases at the proximal femur. BMC Surg. 2018;18:5.
- [Google Scholar]
- Intercalary prosthetic replacement is a reliable solution for metastatic humeral shaft fractures: retrospective, observational study of a single center series. World J Surg Oncol. 2021;19:140.
- [Google Scholar]
- State-of-the-art imaging for diagnosis of metastatic bone disease. Radiologe. 2020;60(Suppl 1):1-16.
- [Google Scholar]
- Bone grafts and biomaterials substitutes for bone defect repair: a review. Bioact Mater. 2017;2(4):224-247.
- [Google Scholar]
- Internal plate fixation of fractures: short history and recent developments. J Orthop Sci. 2006;11(2):118-126.
- [Google Scholar]
- Impact of COVID-19 pandemic on cancer surgical services-AIIMS, New Delhi experience. Indian J Surg Oncol. 2021;12(Suppl 2):294-300.
- [Google Scholar]
- Did COVID-19 related delays in surgical management lead to patient morbidity in the orthopaedic oncological population? Bone Jt Open. 2021;2(4):236-242.
- [Google Scholar]
- Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. Histochem Cell Biol. 2022;158(5):415-434.
- [Google Scholar]
- Health care-associated infections - an overview. Infect Drug Resist. 2018;11:2321-2333.
- [Google Scholar]
- The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101-115.
- [Google Scholar]
- Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012;55(4):1035-1040.e1034.
- [Google Scholar]
- The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4(6):465-473.
- [Google Scholar]
- Perioperative SARS-CoV-2 infections increase mortality, pulmonary complications, and thromboembolic events: a Dutch, multicenter, matched-cohort clinical study. Surgery. 2021;169(2):264-274.
- [Google Scholar]
- Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
- [Google Scholar]
- IMPACT-Restart: the influence of COVID-19 on postoperative mortality and risk factors associated with SARS-CoV-2 infection after orthopaedic and trauma surgery. Bone Joint Lett J. 2020;102-b(12):1774-1781.
- [Google Scholar]
- COVID-positive ankle fracture patients are at increased odds of perioperative surgical complications following open reduction internal fixation surgery. PLoS One. 2021;16(12)
- [Google Scholar]
- Clinical characteristics and perioperative complication profiles of COVID-19-positive patients undergoing hip fracture surgery. J Am Acad Orthop Surg Glob Res Rev. 2021;5(10)
- [Google Scholar]
- Increased complications in patients who test COVID-19 positive after elective surgery and implications for pre and postoperative screening. Am J Surg. 2022;223(2):380-387.
- [Google Scholar]
- Association of time to surgery after COVID-19 infection with risk of postoperative cardiovascular morbidity. JAMA Netw Open. 2022;5(12)
- [Google Scholar]
- The risk of postoperative complications after major elective surgery in active or resolved COVID-19 in the United States. Ann Surg. 2022;275(2):242-246.
- [Google Scholar]
- Timing of surgery after recovery from coronavirus disease 2019 (COVID-19) infection. Infect Control Hosp Epidemiol. 2021;42(6):790-791.
- [Google Scholar]
- Key considerations for elective surgery in patients who previously had COVID-19. AORN J. 2022;115(1):P4-p6.
- [Google Scholar]
- Surgical considerations in patients with COVID-19: what orthopaedic surgeons should know. J Bone Joint Surg Am. 2020;102(11)
- [Google Scholar]
- Surgical management of patients with COVID-19 infection. Recommendations of the Spanish association of surgeons. Cir Esp (Engl Ed). 2020;98(5):251-259.
- [Google Scholar]
- Making a joint decision regarding the timing of surgery for elective arthroplasty surgery after being infected with COVID-19: a systematic review. J Arthroplasty. 2022;37(10):2106-2113.e2101.
- [Google Scholar]
- Estimating the impact of extended delay to surgery for stage I non-small-cell lung cancer on survival. Ann Surg. 2021;273(5):850-857.
- [Google Scholar]
- Surgery in COVID-19 patients: operational directives. World J Emerg Surg. 2020;15(1):25.
- [Google Scholar]
- A review of current interventions for COVID-19 prevention. Arch Med Res. 2020;51(5):363-374.
- [Google Scholar]
- Surgical management of metastatic bone disease. J Bone Joint Surg Am. 2009;91(6):1503-1516.
- [Google Scholar]
- Vascular trauma as a result of therapeutic procedures for the treatment of malignancy. J Vasc Surg. 1991;14(3):314-319.
- [Google Scholar]
- Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin Cancer Biol. 2011;21(2):99-106.
- [Google Scholar]
- Mortality of patients with COVID-19 who undergo an elective or emergency surgical procedure: a systematic review and meta-analysis. ANZ J Surg. 2021;91(1-2):33-41.
- [Google Scholar]

